Health Care • Medical/Dental Instruments
$2.99 ▼ -0.24
(-7.43%)
MKT CAP: $149.1M • VOL: 165.2K
52W L $3 52W H $7
KRMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $41.1M | $33.6M | $28.5M |
| YoY Revenue Growth % | +22.2% | +18.0% | — |
| Gross Profit | $25.6M | $21.3M | — |
| Gross Margin % | 62.3% | 63.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$3.0M | -$6.4M | -$10.3M |
| Operating Margin % | -7.2% | -19.2% | -36.0% |
| Net Income (GAAP) | -$2.6M | -$6.1M | -$13.7M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $462.4K | -$319.7K | -$4.9M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $462.4K | -$319.7K | -$4.9M |
| FCF Margin % | 1.1% | -1.0% | -17.2% |
| Return on Invested Capital (ROIC %) | -28.7% | -45.0% | — |
| Cash & Short-Term Equivalents | $8.9M | $9.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $17.0M | $16.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KRMD.